Sphera Funds Management LTD. bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 52,097 shares of the biopharmaceutical company's stock, valued at approximately $2,042,000. Sphera Funds Management LTD. owned about 0.07% of Xenon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Quarry LP bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $78,000. Blue Trust Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 140.3% in the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after buying an additional 1,414 shares during the period. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $101,000. KBC Group NV boosted its holdings in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 780 shares during the period. Finally, Magnetar Financial LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $210,000. Institutional investors own 95.45% of the company's stock.
Analyst Ratings Changes
Several research firms have recently commented on XENE. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Wells Fargo & Company decreased their price target on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group decreased their price target on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a report on Thursday, April 17th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $54.82.
Get Our Latest Research Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Trading Up 2.2%
Xenon Pharmaceuticals stock traded up $0.66 during midday trading on Monday, reaching $30.95. 753,057 shares of the stock traded hands, compared to its average volume of 512,533. The firm has a fifty day moving average price of $34.10 and a two-hundred day moving average price of $37.91. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -10.98 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same period in the prior year, the company posted ($0.62) earnings per share. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
